Brachytherapy, also known as internal radiation therapy, is a type of radiotherapy in which radiation is delivered directly to a cancerous tumor in the body via a source placed close or next to it. The source emits gamma rays that target cancer cells while minimizing harm to healthy tissue nearby. Depending on the severity of the disease and its damage, brachytherapy is given at a Low Dose Rate (LDR) or a High Dose Rate (HDR). Small radioactive seeds are permanently implanted in or around the tumor in LDR, whereas radioactive sources are removed from the patient's body at the end of each session in HDR, which is utilized in high-risk tumors.
Argon Medical Devices
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Brachytherapy has been shown to be an exceptionally successful treatment choice for cervical, skin, and breast cancers, which is fueling market expansion. Furthermore, the availability of high-quality brachytherapy equipment that delivers precise and very localized radiation doses to tiny tumors has increased patient and medical professional acceptance of the therapy.
Growing medical tourism across the world, as well as increased knowledge of the benefits of brachytherapy, its cost-effectiveness, and higher cure rate when compared to surgery or external beam treatment (EBT), is propelling the industry forward.
In 2020, the HDR brachytherapy category led the market, accounting for 71.2 percent of total revenue.
This category is predicted to develop due to the launch of innovative products such as GammaTile for the treatment of brain cancer. IsoRay gained FDA 510K approval for this device in July 2018, which employs Cesium-131 seeds, which have a lower risk of side effects than other regularly used LDR isotopes.
Note: Although care has been taken to maintain the highest levels of accuracy in Fatpos Global’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Select License Type
US : +1 (716) 218-3733
UK : +44 (208) 1235555
Select License Type
FATPOS CLIENT Appriciation DURING THE PROJECT